Cytokinetics (CYTK) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Cytokinetics (NASDAQ: CYTK):

• 5/12/2026 – Cytokinetics had its price target raised by JPMorgan Chase & Co. from $92.00 to $97.00. They now have an “overweight” rating on the stock.
• 5/11/2026 – Cytokinetics had its price target raised by HC Wainwright from $136.00 to $140.00. They now have a “buy” rating on the stock.
• 5/9/2026 – Cytokinetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/7/2026 – Cytokinetics had its price target raised by Wells Fargo & Company from $95.00 to $105.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Cytokinetics had its price target raised by Morgan Stanley from $90.00 to $103.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Cytokinetics was given a new $119.00 price target by UBS Group AG.
• 5/6/2026 – Cytokinetics had its price target raised by Royal Bank Of Canada from $101.00 to $119.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Cytokinetics had its price target raised by Stifel Nicolaus from $98.00 to $108.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Cytokinetics was given a new $106.00 price target by Truist Financial Corporation.
• 5/5/2026 – Cytokinetics had its price target raised by Needham & Company LLC from $85.00 to $102.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Cytokinetics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/10/2026 – Cytokinetics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $95.00 price target on the stock.
• 4/6/2026 – Cytokinetics had its price target raised by Barclays PLC from $87.00 to $95.00. They now have an “overweight” rating on the stock.
• 4/2/2026 – Cytokinetics was upgraded by Barclays PLC to “strong-buy”.
• 3/18/2026 – Cytokinetics had its price target raised by Mizuho from $84.00 to $100.00. They now have an “outperform” rating on the stock.
• 3/17/2026 – Cytokinetics had its price target raised by JPMorgan Chase & Co. from $74.00 to $75.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, EVP Fady Ibraham Malik sold 12,033 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $747,850.95. Following the completion of the transaction, the executive vice president owned 153,902 shares of the company’s stock, valued at approximately $9,565,009.30. This trade represents a 7.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert I. Blum sold 36,601 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $2,274,752.15. Following the transaction, the chief executive officer directly owned 430,330 shares of the company’s stock, valued at $26,745,009.50. This represents a 7.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 177,476 shares of company stock valued at $11,294,769. Corporate insiders own 2.60% of the company’s stock.

Cytokinetics, Inc is a late?stage biopharmaceutical company focused on the discovery and development of novel small?molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.